Phosphogluconate dehydrogenase (PGD), also called 6-phosphogluconate dehydrogenase (6PGD), is a 53 kDa protein and is part of pentose phosphate pathway. The PGD gene is mapped to human chromosome 1p36.22.
Synonyms: Anti-phosphogluconate dehydrogenase
Storage: -20C
Application: All Prestige Antibodies Powered by Atlas Antibodies are developed and validated by the Human Protein Atlas (HPA) project (www.proteinatlas.org)and as a result, are supported by the most extensive characterization in the industry. The Human Protein Atlas project can be subdivided into three efforts: Human Tissue Atlas, Cancer Atlas, and Human Cell Atlas. The antibodies that have been generated in support of the Tissue and Cancer Atlas projects have been tested by immunohistochemistry against hundreds of normal and disease tissues and through the recent efforts of the Human Cell Atlas project, many have been characterized by immunofluorescence to map the human proteome not only at the tissue level but now at the subcellular level. These images and the collection of this vast data set can be viewed on the Human Protein Atlas (HPA) site by clicking on the Image Gallery link. To view these protocols and other useful information about Prestige Antibodies and the HPA, visit sigma.com/prestige.
Biochem Physiol Actions: Phosphogluconate dehydrogenase PGD catalyzes the conversion of 6-phosphogluconate (6-PG) to ribulose and 5-phosphate and generates nicotinamide adenine dinucleotide phosphate (NADPH). It plays a crucial role in mammalian sperm competence and fertility. Polymorphism in the gene locus of PGD is involved in the pathogenesis of hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC). PGD is upregulated in anaplastic thyroid carcinoma (ATC) and PGD inhibition reverses doxorubicin resistance in cancer cells. Suppression of PGD by physcion inhibitor hampers lipogenesis and halts carcinogenesis.
Legal Information: Prestige Antibodies is a registered trademark of Sigma-Aldrich Co. LLC